{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:49Z","timestamp":1786997929032,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.urolonc.2010.06.012","type":"journal-article","created":{"date-parts":[[2010,9,27]],"date-time":"2010-09-27T09:41:25Z","timestamp":1285580485000},"page":"421-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"Chung-Hsin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Ju","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Tung","family":"Shun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-How","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Jeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong-Shiau","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2010.06.012_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib2","first-page":"29","article-title":"Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions)","volume":"378","author":"Bouffioux","year":"1992","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.urolonc.2010.06.012_bib3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer?","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2010.06.012_bib4","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumor recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2010.06.012_bib6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumor recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2010.06.012_bib7","first-page":"962","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus vs. transurethral resection plus mitomycin C vs. transurethral resection plus bacillus Calmette-Guerin","volume":"156","author":"Krege","year":"1996","journal-title":"Participating Clinics J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0022-5347(01)64484-7","article-title":"Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid, and transurethral resection alone","volume":"158","author":"Kurth","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2008.11.030","article-title":"Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer","volume":"75","author":"Lin","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.06.012_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11864-009-0101-9","article-title":"Systemic therapy of advanced urothelial cancer","volume":"10","author":"Vaishampayan","year":"2009","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00345-006-0113-z","article-title":"Neoadjuvant chemotherapy for bladder cancer","volume":"24","author":"Black","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer","volume":"163","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib13","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-5347(01)61606-9","article-title":"Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: Short- and long-term followup","volume":"161","author":"Solsona","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00428-002-0633-x","article-title":"The WHO\/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer","volume":"441","author":"Busch","year":"2002","journal-title":"Virchows Arch"},{"key":"10.1016\/j.urolonc.2010.06.012_bib16","series-title":"TNM Classification of Malignant Tumors","first-page":"187","article-title":"Urinary bladder","author":"Sobin","year":"1997"},{"key":"10.1016\/j.urolonc.2010.06.012_bib17","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib18","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1097\/01.ju.0000181799.81119.fc","article-title":"Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy","volume":"174","author":"Herr","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1590\/S1677-55382005000300003","article-title":"A 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer","volume":"31","author":"Cheng","year":"2005","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s002800050831","article-title":"Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: A randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone","volume":"42","author":"Naito","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0090-4295(82)90574-X","article-title":"Single and sequential combination intravesical chemotherapy of murine bladder cancer","volume":"19","author":"Soloway","year":"1982","journal-title":"Urology"},{"issue":"Suppl","key":"10.1016\/j.urolonc.2010.06.012_bib22","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1007\/BF00686940","article-title":"Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer","volume":"30","author":"Isaka","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2008.11.030","article-title":"Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer","volume":"75","author":"Lin","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.06.012_bib24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11864-009-0101-9","article-title":"Systemic therapy of advanced urothelial cancer","volume":"10","author":"Vaishampayan","year":"2009","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00345-006-0113-z","article-title":"Neoadjuvant chemotherapy for bladder cancer","volume":"24","author":"Black","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-5347(17)36577-1","article-title":"Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: Results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin","volume":"148","author":"Bouffioux","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.06.012_bib27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(19820901)50:5<863::AID-CNCR2820500509>3.0.CO;2-Q","article-title":"Intravesical cisplatin for superficial bladder tumors","volume":"50","author":"Blumenreich","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2010.06.012_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910001717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910001717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:59:09Z","timestamp":1761040749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143910001717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1078143910001717"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.06.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}